Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Chardan Capital
- Piper Sandler
- JP Morgan
- B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Achilles Therapeutics
What is the target price for Achilles Therapeutics (ACHL)?
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Chardan Capital on August 7, 2023. The analyst firm set a price target for $11.00 expecting ACHL to rise to within 12 months (a possible 1096.04% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Chardan Capital, and Achilles Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Achilles Therapeutics (ACHL) is trading at is $0.92, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.